TEVA NEUROSCIENCE, INC.
PARSIPPANY, NJ

TEVA NEUROSCIENCE, INC., Parsippany

We are more than just a typical pharmaceutical company. We are the leading generics company in the world. Responsibility informs every part of our business. Teva is working every day to make quality healthcare accessible. As a manufacturer of specialty and generic pharmaceuticals, Teva provides both new and innovative therapies and greater access to affordable medicines. One in every six prescriptions dispensed in the US is a Teva product.* If your question is regarding a specific medical condition or the effects of our products, then you should consult with a healthcare professional, as this form is not designed to answer such questions. How can we help you? To speak with a medical information professional about your medical question or to report an adverse event, side effect, or concern about the quality of a Teva product, call 888-TEVA-USA (888-838-2872).

KEY FACTS ABOUT TEVA NEUROSCIENCE, INC.

Company name
TEVA NEUROSCIENCE, INC.
Status
Active
Filed Number
F00000002113
FEI Number
233023331
Date of Incorporation
April 17, 2000
Age - 25 years
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
http://tevaneuroscience.com
Phones
(888) 838-2872
(888) 483-8279
(800) 503-6897
(888) 477-2629
(202) 412-7076
(267) 468-4329
(610) 786-7335
(913) 777-3343

TEVA NEUROSCIENCE, INC. NEAR ME

Principal Address
400 Interpace Parkway,
Parsippany,
NJ,
07054,
US

See Also

Officers and Directors

The TEVA NEUROSCIENCE, INC. managed by the three persons from Parsippany, West Chester on following positions: President, Vice, Sr.

Sven Dethlefs

Position
President Active
From
Parsippany, NJ, 07054

Brian Shanahan

Position
Vice Active
From
West Chester, PA, 19380

Asaph Naaman

Position
Sr. Active
From
Parsippany, NJ, 07054





Registered Agent is CORPORATION SERVICE COMPANY

Address
1201 HAYS STREET, TALLAHASSEE, FL, 32301

Events

March 14, 2003
NAME CHANGE AMENDMENT
March 14, 2003
REINSTATEMENT
September 21, 2001
REVOKED FOR ANNUAL REPORT

Annual Reports

2023
April 28, 2023
2022
April 7, 2022